deCode

Since the establishment of the company in 1996, deCode has gradually been considered a leading Iceland biotech company. It has become the most important global institution specializing in researching and analyzing the human genome. It also leads the world of biotechnology in the discovery of genetic risk factors for common diseases.

With the unique expertise and population resources, deCode has discovered crucial genetic risk factors for dozens of common diseases consisting from cardiovascular disease to cancer. The gene discovery engine of this company works with a range of unique approaches and resources, comprising detailed genetic and medical data on 500,000 individuals from over the world participating in the discovery, proprietary statistical algorithms, and informatics tools for gathering, analyzing, visualizing, as well as storing large amounts of data. Therefore, This has led to some major discoveries over the past 20 years. Many of their findings have directly implemented life-saving medical interventions that would have been carried out 30 years ago.

It is apparent that deCode is well-positioned to specialize in generating and analyzing whole sequence data for large-scale studies. With a combination of population, the generous participation of numerous people, the genealogies, and high-quality universal healthcare, it is convenient for the institution to make possible very large-scale studies of virtually any common disease.

Founded: 1996

Headquarters: Reykjavik, Iceland

Website: https://www.decode.is/